Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer

被引:32
作者
Cao, Subing [1 ]
Ma, Tianfang [1 ]
Ungerleider, Nathan [2 ]
Roberts, Claire [2 ]
Kobelski, Margaret [1 ]
Jin, Lianjin [1 ]
Concha, Monica [2 ]
Wang, Xia [2 ]
Baddoo, Melody [2 ]
Nguyen, Holly M. [3 ]
Corey, Eva [3 ]
Fazli, Ladan [4 ]
Ledet, Elisa [5 ]
Zhang, Rubin [5 ]
Silberstein, Jonathan L. [5 ]
Zhang, Wensheng [6 ]
Zhang, Kun [6 ]
Sartor, Oliver [5 ]
Dong, Xuesen [4 ]
Flemington, Erik K. [2 ]
Dong, Yan [1 ]
机构
[1] Tulane Univ, Sch Med, Dept Struct & Cellular Biol, Tulane Canc Ctr, 1430 Tulane Ave, New Orleans, LA 70112 USA
[2] Tulane Univ, Sch Med, Dept Pathol, Tulane Canc Ctr, New Orleans, LA 70112 USA
[3] Univ Washington, Dept Urol, Seattle, WA 98195 USA
[4] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada
[5] Tulane Univ, Sch Med, Dept Med, Tulane Canc Ctr, New Orleans, LA 70112 USA
[6] Xavier Univ Louisiana, Dept Comp Sci, Bioinformat Facil, Xavier RCMI Ctr Canc Res, New Orleans, LA USA
基金
美国国家卫生研究院;
关键词
TRANSLATION; EXPRESSION; PROGRESSION; LANDSCAPE;
D O I
10.1038/s41388-019-0947-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Deregulated expression of circular RNAs (circRNAs) is associated with various human diseases, including many types of cancer. Despite their growing links to cancer, there has been limited characterization of circRNAs in metastatic castration-resistant prostate cancer, the major cause of prostate cancer mortality. Here, through the analysis of an exome-capture RNA-seq dataset from 47 metastatic castration-resistant prostate cancer samples and ribodepletion and RNase R RNA-sequencing of patient-derived xenografts (PDXs) and cell models, we identified 13 circRNAs generated from the key prostate cancer driver gene-androgen receptor (AR). We validated and characterized the top four most abundant, clinically relevant AR circRNAs. Expression of these AR circRNAs was upregulated during castration-resistant progression of PDXs. The upregulation was not due to global increase of circRNA formation in these tumors. Instead, the levels of AR circRNAs correlated strongly with that of the linear AR transcripts (both AR and AR variants) in clinical samples and PDXs, indicating a transcriptional mechanism of regulation. In cultured cells, androgen suppressed the expression of these AR circRNAs and the linear AR transcripts, and the suppression was attenuated by an antiandrogen. Using nuclear/cytoplasmic fractionation and RNA in-situ hybridization assays, we demonstrated predominant cytoplasmic localization of these AR circRNAs, indicating likely cytoplasmic functions. Overall, this is the first comprehensive characterization of circRNAs arising from the AR gene. With greater resistance to exoribonuclease compared to the linear AR transcripts and detectability of AR circRNAs in patient plasma, these AR circRNAs may serve as surrogate circulating markers for AR/AR-variant expression and castration-resistant prostate cancer progression.
引用
收藏
页码:7060 / 7072
页数:13
相关论文
共 50 条
  • [21] Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer
    Singh, Krishna B.
    Ji, Xinhua
    Singh, Shivendra V.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (10) : 2079 - 2090
  • [22] Castration-resistant prostate cancer: Adaptive responses in the androgen axis
    Egan, Alison
    Dong, Yan
    Zhang, Haitao
    Qi, Yanfeng
    Balk, Steven P.
    Sartor, Oliver
    CANCER TREATMENT REVIEWS, 2014, 40 (03) : 426 - 433
  • [23] Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer
    Wang, Zhu
    Wu, Dinglan
    Ng, Chi-Fai
    Teoh, Jeremy Yuen-Chun
    Yu, Shan
    Wang, Yuliang
    Chan, Franky L.
    ENDOCRINE-RELATED CANCER, 2018, 25 (01) : 35 - 50
  • [24] Expanding Androgen- and Androgen Receptor Signaling-Directed Therapies for Castration-Resistant Prostate Cancer
    Bastos, Diogo A.
    Dzik, Carlos
    Rathkopf, Dana
    Scher, Howard I.
    ONCOLOGY-NEW YORK, 2014, 28 (08): : 693 - 699
  • [25] Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
    Li, Yingming
    Chan, Siu Chiu
    Brand, Lucas J.
    Hwang, Tae Hyun
    Silverstein, Kevin A. T.
    Dehm, Scott M.
    CANCER RESEARCH, 2013, 73 (02) : 483 - 489
  • [26] Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice
    Wu, Min
    Kim, Sahn-Ho
    Datta, Indrani
    Levin, Albert
    Dyson, Gregory
    Li, Jing
    Kaypee, Stephanie
    Swamy, M. Mahadeva
    Gupta, Nilesh
    Kwon, Ho Jeong
    Menon, Mani
    Kundu, Tapas K.
    Reddy, G. Prem-Veer
    ONCOTARGET, 2015, 6 (08): : 6136 - 6150
  • [27] Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
    Menssouri, Naoual
    Poiraudeau, Loic
    Helissey, Carole
    Bigot, Ludovic
    Sabio, Jonathan
    Ibrahim, Tony
    Pobel, Cedric
    Nicotra, Claudio
    Ngo-Camus, Maud
    Lacroix, Ludovic
    Rouleau, Etienne
    Tselikas, Lambros
    Chauchereau, Anne
    Blanc-Durand, Felix
    Bernard-Tessier, Alice
    Patrikidou, Anna
    Naoun, Natacha
    Flippot, Ronan
    Colomba, Emeline
    Fuerea, Alina
    Albiges, Laurence
    Lavaud, Pernelle
    van de Wiel, Paul
    den Biezen, Eveline
    Wesseling-Rozendaal, Yvonne
    Ponce, Santiago
    Michiels, Stefan
    Massard, Christophe
    Gautheret, Daniel
    Barlesi, Fabrice
    Andre, Fabrice
    Besse, Benjamin
    Scoazec, Jean-Yves
    Friboulet, Luc
    Fizazi, Karim
    Loriot, Yohann
    CLINICAL CANCER RESEARCH, 2023, 29 (21) : 4504 - 4517
  • [28] Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer
    Russo, Joshua W.
    Liu, Xiaming
    Ye, Huihui
    Calagua, Carla
    Chen, Sen
    Voznesensky, Olga
    Condulis, James
    Ma, Fen
    Taplin, Mary-Ellen
    Einstein, David J.
    Balk, Steven P.
    Chen, Shaoyong
    CANCER LETTERS, 2018, 438 : 97 - 104
  • [29] Androgen receptor: what we know and what we expect in castration-resistant prostate cancer
    Cai, Zhonglin
    Chen, Weijie
    Zhang, Jianzhong
    Li, Hongjun
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2018, 50 (10) : 1753 - 1764
  • [30] Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions
    Leibowitz-Amit, R.
    Joshua, A. M.
    CURRENT ONCOLOGY, 2012, 19 : S22 - S31